SignalXSignalX

HAE HAEMONETICS CORP

FY2025 10-K
Filed: May 21, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR
HAEMONETICS CORP Overview

HAEMONETICS CORP (HAE) filed its fiscal year 2025 10-K annual report with the SEC on May 21, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business: Medical devices and technologies for plasma collection, blood centers, and hospitals
  • • Emphasis on Plasma and Hospital segments as primary growth drivers; Blood Center focused on targeted plasma and platelet opportunities
+3 more insights

Management Discussion & Analysis

  • • Revenue $1.361B, up 4.0% YoY; Hospital segment up 23.7% ($564M vs $456M), Plasma down 6.0% ($535M vs $570M), Blood Center down 7.8% ($261M vs $283M)
  • • Operating margin 16.3% vs 12.6%; gross margin 55.0% vs 52.8%; net income margin 12.3% vs 9.0%
+3 more insights

Risk Factors

  • • Regulatory risk from SEC Rule 10b5-1 affecting timing and execution of $500M share repurchase program through April 2028
  • • Share repurchase program could increase stock price volatility and reduce market liquidity for common stock
+3 more insights

Financial Summary
XBRL

Revenue

$1.4B

Net Income

$168M

Gross Margin

55.0%

Operating Margin

16.3%

Net Margin

12.3%

ROE

20.4%

Total Assets

$2.5B

EPS (Diluted)

$3.31

Operating Cash Flow

$182M

Source: XBRL data from HAEMONETICS CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on HAEMONETICS CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available